We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Knight Therapeutics Inc (GUD) Common Stock NPV

Sell:5.72 CAD Buy:5.88 CAD Change: 0.05 CAD (0.86%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:5.72 CAD
Buy:5.88 CAD
Change: 0.05 CAD (0.86%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:5.72 CAD
Buy:5.88 CAD
Change: 0.05 CAD (0.86%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

Contact details

Address:
3400 De Maisonneuve Blvd W
MONTREAL
H3Z 3B8
Canada
Telephone:
+1 (514) 4844483
Website:
https://www.gud-knight.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GUD
ISIN:
CA4990531069
Market cap:
583.43 million CAD
Shares in issue:
101.19 million
Sector:
Pharmaceuticals
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Jonathan Goodman
    Executive Chairman of the Board
  • Samira Sakhia
    President, Chief Executive Officer, Director
  • Arvind Utchanah
    Chief Financial Officer
  • Jeff Martens
    Global Vice President - Commercial
  • Stephani Saverio
    Global Vice President - Business Development
  • Amal Khouri
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.